Keep an eye on this tech stock - after years of loses, rights issues, etc things look to be moving in the right direction. Tipped by Redmayne last year it could be a winner.

realistic , thanks for that , saw all the volume but could not make out what the h*ll was going on. still unsure cos funds can move a large amount of shares around without it meaning much

Something is going on.PTI should reach 200 this year.It consolidated a stable trading range of 10p last year.Turnover up 21% 2004.Specialising in toxicity treatments,it is a niche player.VORAXAZE is very interesting because of its use in counteracting the negative effects of chemotherapy...launch in 2006,maybe sooner
14 Jan..DIRECTOR BUYS.Dr.Tony Atkinson buys 300000 shares....does'nt seem a lot
BUT...
20 Jan.Fidelity buys 3,196,327.
Charts look good,so BUY boys BUY.....
I will...always nice to know that there's some anti snakebite treatment out there!

This sp looking very weak recently.The only bad news I can find is the recent load of share options granted to the directors.This obviously dliutes existing shareholder value. Apart from that everthing else seems to be going to plan.Unless anyone out there knows different? Any news ethel?

Yes, I was very enthusiastic back in Jan...and still am but there was no response to my message so I forgot about it waiting for the moving averages to look better.The institutions have accepted PTI as a relatively "safe" prospect compared with some of the biotechs.
The Crofab market est.potential is 80mln dollars.BUT,in Oncology thay have Voraxaze with US and EU MARKETING applications PLANNED for Q2 this year.The initial opportunity estimate is upto 200 mln dollars.At the moment Voraxaze is sold to named patients only.PTI also have Prion and BSE and CJD diagnostics.In the pipeline-Angiotensin Vaccine for Hypertension and NQO2 for liver cancer in clinical development.Cytofab for severe sepsis is going into phase 111 trials.Maybe we will have news about discussions with licensing partners for the latter.Framlington et al are invested in them.Have'nt checked the price yet,but if the averages look good then I shall go in.This share is normally quite predictable and not volatile when it starts to go up.But you see it's not just about snake bite antidotes...this is a great crowd with good products for sale...not just dreams.

Thanks for that ethel. I think I'll stick with them for another year.I bought some at the early rights for 16p so I'm well in front but lately things have been so quiet.We must be thankful that the institutions are prepared to be patient.

Hello again,Realistic...still there?
PTI been tipped for last two weeks.rns today....still no sp move.
Moving averages show hint of a change and am tempted back in,but still wary of the way this company has been ignored by investors.
With the small caps the way they are at the moment,it is difficult to feel confident about particular stocks,even when the fundamentals seem O.K.The sp could be shorted down in the absence of news.As it is ,the one year chart shows that the sp is where it was last autumn,when there was a dir.buy at 50p followed by a nice rise ...the 38 day moving averages even look the same as they did then!
Well,I think I'll go for it,wish us luck and all those others out there,whoever you are.
Ethel

On the move again shortly - moving north big time.

How/what do you know?

Now that would be telling.

Come on,let us share your secret,Transco!
Whatever,the sp is finally moving north.

Just read my earlier posts last year and read between the lines.
This is a top class business, building a long term sound future.

Its time for protherics to fly !!!!!!!!!!!

well still it goes up and up... takeover talk about and discounted rights issue

up on a bad day - plus good volume.

Has nobody noticed this move!!
Come on chaps credit where its due.
What a mover!!! and more to come...

Transco - are you still in? I've taken the plunge today. Downside seems limited whilst upside potential is superb. Fingers crossed.

Protherics PLC
12 January 2006


CYTOFABTM LICENSING AGREEMENT BETWEEN PROTHERICS AND ASTRAZENECA BECOMES
EFFECTIVE FOLLOWING HART-SCOTT-RODINO CLEARANCE


London, UK, Nashville, TN, 12 January 2006 - Following the announcement on 8
December 2005, of the licensing agreement between Protherics and AstraZeneca for
the global development and commercialisation of Protherics' anti-sepsis product
CytoFabTM, it is further announced that the agreement has become effective
following the expiry of the Hart-Scott-Rodino waiting period in the US.

This triggers an immediate initial payment to Protherics of 16.3 million and a
7.5 million equity investment by AstraZeneca in Protherics. The agreement has
further potential milestone payments worth up to 171 million and Protherics
will also receive a 20 percent net royalty on the net global sales of CytoFabTM.

Protherics PLC
20 January 2006


PROTHERICS PLC

NOTIFICATION OF MAJOR INTERESTS IN SHARES

20 January 2005: Protherics PLC (the 'Company'), the biopharmaceutical company
focused on critical care and oncology, received notification today from
Perpetual Income & Growth Investment Trust plc on behalf of INVESCO Asset
Management Limited that Perpetual Income & Growth Investment Trust plc is the
beneficial owner of 10,115,137 ordinary shares representing 3.92% of the issued
share capital of the Company.

This notification follows an increase in the Company's issued share capital to
258,328,129 ordinary shares.

Protherics PLC
20 January 2006



PROTHERICS PLC

NOTIFICATION OF MAJOR INTERESTS IN SHARES


20 January 2006: Protherics PLC, the biopharmaceutical company focused on
critical care and oncology (the 'Company'), received notification on 19 January
2006 from Aviva plc that, as at 18 January 2006, Aviva plc and its subsidiaries
held a beneficial interest in 12,383,731 ordinary shares, representing 4.79% of
the issued share capital of the Company, and a total interest in 27,603,457
ordinary shares, representing 10.68% of the issued share capital of the Company.

This notification follows an increase in the Company's issued share capital to
258,328,129 ordinary shares.

Protherics PLC
20 January 2006



PROTHERICS PLC


NOTIFICATION OF MAJOR INTERESTS IN SHARES


20 January 2005: Protherics PLC (the 'Company'), the biopharmaceutical company
focused on critical care and oncology, received notification on 19 January 2006
from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group
Company ('AXA S.A.') that, on 18 January 2006, AXA S.A. held an interest in
32,099,803 ordinary 2p shares (the 'Shares') in the share capital of the Company
(12.43%).



The Shares are represented by a beneficial interest in 10,000 ordinary shares
(0.004%) and a non-beneficial interest in 32,089,803 ordinary shares (12.422%).



This notification follows an increase in the Company's issued share capital to
258,328,129 ordinary shares.